T. T. Pham, G. Barratt, J. P. Michel, P. M. Loiseau, and M. Saint-pierre-chazalet, Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates, Colloids Surf. B Biointerfaces, vol.106, pp.224-233, 2013.

R. Reithinger, J. Dujardin, H. Louzir, C. Pirmez, B. Alexander et al., Cutaneous leishmaniasis, Lancet Infect. Dis, vol.7, pp.581-596, 2007.

T. S. Tiuman, A. O. Santos, T. Ueda-nakamura, B. P. Filho, and C. V. Nakamura, Recent advances in leishmaniasis treatment, Int. J. Infect. Dis, vol.15, 2011.

N. Singh, M. Kumar, and R. K. Singh, Leishmaniasis: current status of available drugs and new potential drug targets, Asian Pac, J. Trop. Med, vol.5, pp.485-497, 2012.

D. C. Soares, C. G. Pereira, M. Â. Meireles, and E. M. Saraiva, Leishmanicidal activity of a supercritical fluid fraction obtained from Tabernaemontana catharinensis, Parasitol. Int, vol.56, pp.135-139, 2007.

J. Alvar, I. D. Vélez, C. Bern, M. Herrero, P. Desjeux et al., Leishmaniasis worldwide and global estimates of its incidence, PloS One, vol.7, 2012.

D. Pace and L. , J. Infect, vol.69, pp.16-26, 2014.

A. Dutta, G. Mandal, C. Mandal, and M. Chatterjee, In vitro antileishmanial activity of Aloe vera leaf exudate: a potential herbal therapy in leishmaniasis, Glycoconj. J, vol.24, pp.81-86, 2007.

P. Mansueto, A. Seidita, G. Vitale, and A. Cascio, Leishmaniasis in travelers: a literature review, Trav. Med. Infect. Dis, vol.12, pp.563-581, 2014.

S. Sundar and J. Chakravarty, Paromomycin in the treatment of leishmaniasis, Expet Opin. Invest. Drugs, vol.17, pp.787-794, 2008.

V. Saranavan and P. Das, Recent progress in drug targets and inhibitors towards combating leishmaniasis, Acta Trop, vol.17, 2018.

B. Zulfiqar, T. B. Shelper, and V. M. Avery, Leishmaniasis drug discovery: recent progress and challenges in assay development, Drug Discov. Today, vol.22, pp.1516-1531, 2017.

A. Souza, D. S. Marins, S. L. Mathias, L. M. Monteiro, M. N. Yukuyama et al., Promising nanotherapy in treating leishmaniasis, Int. J. Pharm, vol.547, pp.421-431, 2018.

S. Kapil, P. K. Singh, and O. Silakari, An update on small molecule strategies targeting leishmaniasis, Eur. J. Med. Chem, vol.157, pp.339-367, 2018.

J. H. No, Visceral leishmaniasis: revisiting current treatments and approaches for future discoveries, Acta Trop, vol.155, pp.113-123, 2016.

P. Mitropoulos, P. Konidas, and M. Durkin-konidas, New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment, J. Am. Acad. Dermatol, vol.63, pp.309-322, 2010.

G. Carneiro, M. G. Aguiar, A. P. Fernandes, and L. A. Ferreira, Drug delivery systems for the topical treatment of cutaneous leishmaniasis, Expet Opin. Drug Deliv, vol.9, pp.1083-1097, 2012.

S. Sundar and J. Chakravarty, An update on pharmacotherapy for Leishmaniasis, Expet Opin. Pharmacother, vol.16, pp.237-252, 2015.

, World Health Organization, Leishmaniasis -Situations and Trends, 2019.

J. Bezerra-de-menezes, C. Guedes, A. Oliveira-petersen, D. Fraga, P. Sampaio et al., Advances in development of new treatment for leishmaniasis, BioMed Res. Int, pp.1-11, 2015.

J. A. Lindoso, J. M. Costa, I. T. Queiroz, and H. Goto, Review of the current treatments for leishmaniases, Res. Rep. Trop. Med, vol.3, pp.69-77, 2012.

H. Goto and J. A. Lindoso, Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis, Expert Rev. Anti Infect. Ther, vol.8, pp.419-433, 2010.

M. Akbari, A. Oryan, and G. Hatam, Application of nanotechnology in treatment of leishmaniasis: a Review, Acta Trop, vol.172, pp.86-90, 2017.

M. Z. Handler, P. A. Patel, R. Kapila, Y. Al-qubati, and R. A. Schwartz, Cutaneous and mucocutaneous leishmaniasis: differential diagnosis, diagnosis, histopathology, and management, J. Am. Acad. Dermatol, vol.73, pp.911-926, 2015.

V. M. Ribeiro, The use of Milteforan® in the treatment of canine visceral leishmaniasis in Brazil, Rev. V&Z Em Minas, vol.131, pp.44-46, 2016.

L. Imbert, S. Cojean, D. Libong, P. Chaminade, and P. M. Loiseau, Sitamaquine-resistance in Leishmania donovani affects drug accumulation and lipid metabolism, Biomed. Pharmacother, vol.68, pp.893-897, 2014.

M. Ghadiri, S. Fatemi, A. Vatanara, D. Doroud, A. R. Najafabadi et al., Loading hydrophilic drug in solid lipid media as nanoparticles: stastitical modeling of entrapment efficiency and particle size, Int. J. Pharm, vol.424, pp.128-137, 2012.

P. W. Nassif, T. F. De-mello, T. R. Navasconi, C. A. Mota, I. G. Demarchi et al., Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review, Parasitology, vol.144, pp.995-1004, 2017.

I. M. Lobo, M. B. Soares, T. M. Correia, L. A. De-freitas, M. I. Oliveira et al., Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy, Trans. R. Soc. Trop. Med. Hyg, vol.100, pp.642-649, 2006.

N. E. Aronson and C. A. Joya, Cutaneous leishmaniasis: updates in diagnosis and management, Infect. Dis. Clin, vol.33, pp.101-117, 2019.

N. E. Aronson, G. W. Wortmann, W. R. Byrne, R. S. Howard, W. B. Bernstein et al., A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection, PLoS Neglected Trop. Dis, vol.4, p.628, 2010.

J. A. Cardona-arias, L. López-carvajal, M. P. Tamayo-plata, and I. D. Vélez, Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia, Health, vol.18, 2018.

L. Lopez, M. Robayo, M. Vargas, I. D. Vélez, and T. , An Alternative for the Treatment of, American Cutaneous Leishmaniasis, vol.13, pp.1-7, 2012.

P. Layegh, F. Pezeshkpoor, A. H. Soruri, P. Naviafar, and T. Moghiman, Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children, Am. J. Trop. Med. Hyg, vol.80, pp.172-175, 2009.

A. Asilian, A. Sharif, G. Faghihi, S. Enshaeieh, F. Shariati et al., Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis, Int. J. Dermatol, vol.43, pp.736-738, 2004.

S. Oliveira, E. J. Da-ordem-trahamane, J. Monteiro, G. P. Santos, P. Crugeira et al., Leishmanicidal effect of antiparasitic photodynamic therapy-ApPDT on infected macrophages, Laser Med. Sci, vol.32, pp.1959-1964, 2017.

E. Ricci-junior, L. B. De-oliveira-de-siqueira, R. A. Rodrigues, F. Sancenón, R. Martínez-máñez et al., Nanocarriers as phototherapeutic drug delivery system: appraisal of three different nanosystems in an in vivo and in vitro exploratory study, Photodiagnosis Photodyn, Ther, vol.21, pp.43-49, 2018.

L. B. De-oliveira-de-siqueira, V. Da-silva-cardoso, I. A. Rodrigues, A. L. Vazquez-villa, E. P. Santos et al., Development and evaluation of zinc phthalocyanine nanoemulsions for use in photodynamic therapy for Leishmania spp, Nanotechnology, vol.28, issue.6, p.65101, 2017.

E. M. Van-der, D. J. Snoek, J. J. Robinson, H. A. Van-hellemond, and . Neumann, A review of photodynamic therapy in cutaneous leishmaniasis, J. Eur. Acad

, Dermatol. Venereol, vol.22, pp.918-922, 2008.

L. De-almeida, A. T. Fujimura, M. L. Del-cistia, B. Fonseca-santos, K. B. Imamura et al., Nanotechnological strategies for treatment of leishmaniasis-a review, J. Biomed. Nanotechnol, vol.13, pp.117-133, 2017.

A. Pujol-brugués, A. C. Calpena-campmany, C. Riera-lizandra, L. Halbaut-bellowa, and B. , Clares-Naveros, Development of a liquid chromatographic method for the quantification of paromomycin. Application to in vitro release and ex vivo permeation studies, Spectrochim. Acta Part A Mol. Biomol. Spectrosc, vol.133, pp.657-662, 2014.

A. P. Brugués, B. C. Naveros, A. C. Calpena-campmany, P. H. Pastor, R. F. Saladrigas et al., Developing cutaneous applications of paromomycin entrapped in stimuli-sensitive block copolymer nanogel dispersions, Nanomedicine, vol.10, pp.227-240, 2015.

R. N. Davidson, M. Boer, K. Ritmeijer, and P. , Trans. R. Soc. Trop. Med. Hyg, vol.103, pp.653-660, 2009.

, United States Pharmacopeia, Paromomycin Sulfate, 2012.

, Paromomycin ChemIDplus, 2019.

, The International Pharmacopoeia -Eighth Edition -World Health Organization, Paromomycin Sulfate (Paromomycini Sulfas), 2018.

W. Khan and N. Kumar, Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation, J. Drug Target, vol.19, pp.239-250, 2011.

A. Banerjee, M. De, and N. Ali, Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation, antimicrob, Agents Chemother, vol.55, pp.1661-1670, 2011.

L. De-almeida, B. Fonseca-santos, P. Michels, L. De-almeida, A. T. Fujimura et al., Nanotechnological Strategies for Treatment of Leishmaniasis -A Review Nanotechnological Strategies for Treatment of Leishmaniasis -A Review, 2017.

W. Khan, S. S. Sharma, and N. Kumar, Bioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheres, Drug Test. Anal, vol.5, pp.453-460, 2013.

J. Chakravarty and S. Sundar, Drug resistance in leishmaniasis, J. Global Infect. Dis, vol.2, pp.167-176, 2010.

M. H. Kharaji, D. Doroud, T. Taheri, and S. Rafati, Drug targeting to macrophages with solid lipid nanoparticles harboring paromomycin: an in vitro evaluation against L. Major and L. Tropica, AAPS PharmSciTech, vol.17, pp.1110-1119, 2015.

A. Khatami, A. Firooz, F. Gorouhi, and Y. Dowlati, Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials, J. Am. Acad. Dermatol, vol.57, 2007.

J. El-on, G. P. Jacobs, E. Witztum, and C. L. Greenblatt, Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals, Antimicrob, Agents Chemother, vol.26, pp.745-751, 1984.

J. El-on, S. Halevy, M. H. Grunwald, L. Weinrauch, and M. B. Sheva, Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major : a doubleblind control study, J. Am. Acad. Dermatol, vol.27, pp.227-231, 1992.

G. Krause and A. Kroeger, Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador, Trans. R. Soc. Trop. Med. Hyg, vol.88, pp.90517-90524, 1994.

O. Ozgoztasi and I. Baydar, A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey, Int. J. Dermatol, vol.36, pp.61-63, 1997.

B. A. Arana, C. E. Mendoza, N. R. Rizzo, and A. Kroeger, Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala, Am. J. Trop. Med. Hyg, vol.65, pp.466-470, 2001.

A. Asilian and M. Davami, Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of old world cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial, Clin. Exp. Dermatol, vol.31, pp.634-637, 2006.

A. Ben-salah, N. Ben-messaoud, E. Guedri, A. Zaatour, N. Ben-alaya et al., Topical paromomycin with or without gentamicin for cutaneous leishmaniasis, N. Engl. J. Med, vol.368, pp.524-532, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-00793585

M. Grogl, B. G. Schuster, W. Y. Ellis, and J. D. Berman, Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin, J. Parasitol, vol.85, pp.354-359, 1999.

A. D. Bryceson, A. H. Moody, and A. Murphy, Treatment of 'old world' cutaneous leishmaniasis with aminosidine ointment: results of an open study in london, Trans. R. Soc. Trop. Med. Hyg, vol.88, pp.90308-90313, 1994.

F. A. Neva, C. Ponce, E. Ponce, R. Kreutzer, F. Moudabber et al., Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin, Trans. R. Soc. Trop. Med. Hyg, vol.91, pp.473-475, 1997.

A. Asilian, T. Jalayer, M. Nilforooshzadeh, R. L. Ghassemi, R. Peto et al., Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran, Bull. World Health Organ, vol.81, pp.353-359, 2003.

F. Iraji and A. Sadeghinia, Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, Ann. Trop. Med. Parasitol, vol.99, pp.3-9, 2005.

R. X. Armijos, M. M. Weigel, M. Calvopiña, M. Mancheno, and R. Rodriguez, Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis, Acta Trop, vol.91, pp.153-160, 2004.

G. Faghihi and R. Tavakoli-kia, Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate, Clin. Exp. Dermatol, vol.28, pp.13-16, 2003.

B. Shazad, B. Abbaszadeh, and A. Khamesipour, Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major, Eur. J. Dermatol, vol.15, pp.85-87, 2005.

A. Ben-salah, P. A. Buffet, G. Morizot, N. Ben-massoud, A. Zâatour et al., WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous Leishmaniasis: a phase 2, randomized, double blind, placebo controlled study, PLoS Neglected Trop. Dis, vol.3, p.432, 2009.
URL : https://hal.archives-ouvertes.fr/pasteur-00859427

W. R. Ravis, A. Llanos-cuentas, N. Sosa, M. Kreishman-deitrick, K. M. Kopydlowski et al., Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis, Antimicrob. Agents Chemother, vol.57, pp.4809-4815, 2013.

G. S. Gonçalves, A. P. Fernandes, R. C. Souza, J. E. Cardoso, F. Oliveira-silva et al., Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis, Acta Trop, vol.93, pp.161-167, 2005.

, Gel produzido pela Fiocruz pode revolucionar tratamento da leishmaniose » Isaúde, Isaúde net, 2013.

J. Soto, P. Fuya, R. Herrera, and J. Berman, Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study, Clin. Infect. Dis, vol.26, pp.56-58, 1998.

J. El-on, E. Bazarsky, and R. Sneir, Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod, Exp. Parasitol, vol.116, pp.156-162, 2007.

S. Sundar, T. K. Jha, C. P. Thakur, P. K. Sinha, and S. K. Bhattacharya, Injectable Paromomycin for visceral leishmaniasis in India, N. Engl. J. Med, vol.356, pp.2571-2581, 2007.

K. M. Jamil, R. Haque, R. Rahman, M. A. Faiz, A. T. Bhuiyan et al., Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh, PLoS Neglected Trop. Dis, vol.9, pp.1-11, 2015.

J. D. Berman, Human Leishmaniasis : clinical, diagnostic , and chemotherapeutic developments in the last 10 years, Clin. Infect. Dis, vol.24, pp.684-703, 1997.

A. Musa, E. Khalil, A. Hailu, J. Olobo, M. Balasegaram et al., Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in east africa: a randomised controlled trial, PLoS Neglected Trop. Dis, vol.6, p.1674, 2012.

, pdf;jsessionid=A7218CC35C8295AEFF2801689F3D33FB? sequence=1 accessed, Control of the Leishmaniases -WHO Technical Report Series, vol.949, 2010.

C. Abongomera, F. Gatluak, J. Buyze, and K. Ritmeijer, A comparison of the effectiveness of sodium stibogluconate monotherapy to sodium stibogluconate and paromomycin combination for the treatment of severe post kala azar dermal leishmaniasis in south Sudan -a retrospective cohort study, PloS One, vol.11, pp.1-12, 2016.

R. Kimutai, A. M. Musa, S. Njoroge, R. Omollo, F. Alves et al., Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern africa: results from a pharmacovigilance programme, Clin. Drug Invest, vol.37, pp.259-272, 2017.

R. Rahman, V. Goyal, R. Haque, K. Jamil, A. Faiz et al., Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh, PLoS Neglected Trop. Dis, vol.11, pp.1-15, 2017.

S. Hendrickx, M. Van-den-kerkhof, D. Mabille, P. Cos, P. Delputte et al., Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum, PLoS Neglected Trop. Dis, vol.11, pp.1-10, 2017.

G. Wijnant, K. Van-bocxlaer, V. Yardley, S. Murdan, and S. L. Croft, Efficacy of paromomycin-chloroquine combination therapy in experimental cutaneous leishmaniasis, Antimicrob. Agents Chemother, vol.61, pp.1-8, 2017.

J. Schwartz, E. Moreno, A. Calvo, L. Blanco, C. Fernández-rubio et al., Combination of paromomycin plus human anti-TNF-? antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions, J. Dermatol. Sci, vol.92, pp.78-88, 2018.

D. H. Kim, H. J. Chung, J. Bleys, and R. F. Ghohestani, Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials, PLoS Neglected Trop. Dis, vol.3, pp.1-10, 2009.

, Drugs for Neglected Diseases initiative (DNDi), Diseases & Projects -about Leishmaniasis -Current Treatments, 2019.

A. Jhingran, B. Chawla, S. Saxena, M. P. Barrett, and R. Madhubala, Paromomycin: uptake and resistance in Leishmania donovani, Mol. Biochem. Parasitol, vol.164, pp.111-117, 2009.

V. Maravajhala, N. Dasari, A. Sepuri, and S. Joginapalli, Design and evaluation of niacin microspheres, Indian J. Pharmaceut. Sci, vol.71, pp.663-669, 2010.

C. Tomaro-duchesneau, S. Saha, M. Malhotra, I. Kahouli, and S. Prakash, Microencapsulation for the terapeutic delivery of drugs, live mammalian and bacterial cells, and other biopharmaceutics: current status and future directions, J. Pharm, pp.1-19, 2013.

M. N. Singh, K. S. Hemant, M. Ram, and H. G. Shivakumar, Microencapsulation: a promising technique for controlled drug delivery, Res. Pharm. Sci. Sci, vol.5, pp.65-77, 2010.

T. K. Giri, C. Choudhary, A. Ajazuddin, H. Alexander, D. K. Badwaik et al., Prospects of pharmaceuticals and biopharmaceuticals loaded microparticles prepared by double emulsion technique for controlled delivery, Saudi Pharmaceut, J, vol.21, pp.125-141, 2013.

B. B. Patel, J. K. Patel, S. Chakraborty, and D. Shukla, Revealing facts behind spray dried solid dispersion technology used for solubility enhancement, Saudi Pharmaceut. J, vol.23, pp.352-365, 2015.

W. Khan, R. Kumar, S. Singh, S. K. Arora, and N. Kumar, Paromomycin-loaded albumin microspheres: efficacy and stability studies, vol.5, pp.468-473, 2013.

G. A. Islan, M. Durán, M. L. Cacicedo, G. Nakazato, R. K. Kobayashi et al., Nanopharmaceuticals as a solution to neglected diseases: is it possible?, Acta Trop, vol.170, pp.16-42, 2017.

A. Momeni, M. Rasoolian, A. Momeni, A. Navaei, S. Emami et al., Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis, J. Liposome Res, vol.23, pp.134-144, 2013.

A. Akbarzadeh, R. Rezaei-sadabady, S. Davaran, S. W. Joo, N. Zarghami et al., Liposome : classification , preparation , and applications, Nanoscale Res. Lett, vol.8, 2013.

A. Laouini, C. Jaafar-maalej, I. Limayen-blouza, S. Sfar, C. Charcosset et al., Preparation, characterization and applications of liposomes: state of the art, J. Colloid Sci. Biotechnol, vol.1, pp.147-168, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02002202

D. Williams, A. B. Mullen, A. J. Baillie, and K. C. Carter, Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis, J. Pharm. Pharmacol, vol.50, pp.1351-1356, 1998.

M. M. Gaspar, S. Calado, J. Pereira, H. Ferronha, I. Correia et al., Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems, Nanomed. Nanotechnol. Biol. Med, vol.11, pp.1851-1860, 2015.

L. S. Ferreira, G. A. Ramaldes, E. A. Nunan, and L. A. Ferreira, In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis, Drug Dev. Ind. Pharm, vol.30, pp.289-296, 2004.

M. R. Jaafari, N. Bavarsad, B. S. Bazzaz, A. Samiei, D. Soroush et al., Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible

. Balb/c-mice, Antimicrob. Agents Chemother, vol.53, pp.2259-2265, 2009.

G. Carneiro, D. C. Santos, M. C. Oliveira, A. P. Fernandes, L. S. Ferreira et al., Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis, J. Liposome Res, vol.20, pp.16-23, 2010.

N. Bavarsad, B. S. Bazzaz, A. Khamesipour, and M. R. Jaafari, Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice, Acta Trop, vol.124, pp.33-41, 2012.

H. Kalantari, A. A. Hemmati, N. Bavarsad, A. Rezaie, and S. Ahmadi, Effect of topical nanoliposomes of paromomycin on rats liver and kidney, Jundishapur J. Nat. Pharm. Prod, vol.9, 2014.

V. Mishra, K. K. Bansal, A. Verma, N. Yadav, S. Thakur et al., Solid lipid nanoparticles: emerging colloidal nano drug delivery systems, Pharmaceutics, vol.10, pp.1-21, 2018.

M. Geszke-moritz and M. Moritz, Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies, Mater. Sci. Eng. C, vol.68, pp.982-994, 2016.

M. Ghadiri, A. Vatanara, D. Doroud, and A. R. Najafabadi, Paromomycin loaded solid lipid nanoparticles: characterization of production parameters, Biotechnol. Bioproc. Eng, vol.16, pp.617-623, 2011.

M. Kotmakç?, H. Akbaba, G. Erel, G. Ertan, and G. Kantarc?, Improved method for solid lipid nanoparticle preparation based on hot microemulsions: preparation, characterization, cytotoxicity, and hemocompatibility evaluation, AAPS PharmSciTech, vol.18, pp.1355-1365, 2016.

K. Manjunath, J. S. Reddy, and V. Venkateswarlu, Solid lipid nanoparticles as drug delivery systems, methods find, Exp. Clin. Pharmacol, vol.27, pp.1-20, 2005.

M. Heidari-kharaji, T. Taheri, D. Doroud, S. Habibzadeh, A. Badirzadeh et al., Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model, Parasite Immunol, vol.38, pp.599-608, 2016.

M. Heidari-kharaji, T. Taheri, D. Doroud, S. Habibzadeh, and S. Rafati, Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model, Appl. Microbiol. Biotechnol, vol.100, pp.7051-7060, 2016.

M. Mahinroosta, Z. Farsangi, A. Allahverdi, and Z. Shakoori, Hydrogels as intelligent materials: a brief review of synthesis, properties and applications, Mater. Today Chem, vol.8, pp.42-55, 2018.

E. M. Ahmed, Hydrogel : preparation , characterization , and applications : a review, J. Adv. Res, vol.6, pp.105-121, 2015.

A. M. Santos, E. F. Noronha, L. A. Ferreira, C. O. Carranza-tamayo, E. Cupolillo et al., Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials, Rev. Soc. Bras. Med. Trop, vol.41, pp.444-448, 2008.

S. V. Mussi, A. P. Fernandes, and L. A. Ferreira, Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis, Parasitol. Res, vol.100, pp.1221-1226, 2007.

M. G. Aguiar, D. L. Silva, F. A. Nunan, E. A. Nunan, A. P. Fernandes et al., Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens, J. Antimicrob. Chemother, vol.64, pp.1234-1240, 2009.

M. G. Aguiar, A. M. Pereira, A. P. Fernandes, and L. A. Ferreira, Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis, Antimicrob, Agents Chemother, vol.54, pp.4699-4704, 2010.

E. De-morais-teixeira, M. G. Aguiar, B. Soares-de-souza-lima, L. A. Ferreira, and A. Rabello, Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis, J. Antimicrob. Chemother, vol.70, pp.3283-3290, 2015.

J. Schwartz, E. Moreno, C. Fernández, I. Navarro-blasco, P. A. Nguewa et al., Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation, Eur. J. Pharmaceut. Sci, vol.62, pp.309-316, 2014.

D. Plano, Y. Baquedano, D. Moreno-mateos, M. Font, A. Jiménez-ruiz et al., Selenocyanates and diselenides: a new class of potent antileishmanial agents, Eur. J. Med. Chem, vol.46, pp.3315-3323, 2011.

K. Kathe and H. Kathpalia, Film forming systems for topical and transdermal drug delivery, Asian J. Pharm. Sci, vol.12, pp.487-497, 2017.

K. Frederiksen, R. H. Guy, and K. Petersson, Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin, Eur. J. Pharm. Biopharm, vol.91, pp.9-15, 2015.

S. Karki, H. Kim, S. J. Na, D. Shin, K. Jo et al., Thin films as an emerging platform for drug delivery, Asian J. Pharm. Sci, vol.11, pp.559-574, 2016.

S. Tolouei, S. J. Hasheminia, M. Narimani, A. Khamesipour, M. A. Shatalebi et al., Leishmanicidal activity of films containing paromomycin and gentamicin sulfate both in vitro and in vivo, J. Parasitol, vol.6, pp.60-65, 2011.

S. F. Gomes, E. De-a.-nunan, and L. A. Ferreira, Influence of the formulation type (o/w, w/o/w emulsions and ointment) on the topical delivery of paromomycin, Rev. Bras. Ciencias Farm, vol.40, pp.345-352, 2010.

I. R. Nogueira, G. Carneiro, M. I. Yoshida, R. B. De-oliveira, and L. A. Ferreira, Preparation, characterization, and topical delivery of paromomycin ion pairing, Drug Dev. Ind. Pharm, vol.37, pp.1083-1089, 2011.